Securus Technologies rectifies GTL’s Press Statements

Securus Technologies is a communication firm that has mainly specialized in offering services to correctional facilities in the United States. The operations of the enterprise are run from its headquarters in Dallas, Texas. The company currently has a broad customer base of 3450 institutions that have over 1.2 million prisoners. The focus of its services is correcting, public safety, investigation, and monitoring. It has been connecting the inmates and their loved ones. Securus recently offered a press statement to correct various reports that GTL had issued in the past. GTL published a lot of allegations that are considered as misleading and untrue. Securus, therefore, decided to react to the claims by offering factual information that elucidates the information that was released by its rival.


The CEO of Securus, Richard A. Smith, believes that GTL as a company understands the costs that incurred in addressing patent litigations. The cases consume millions of dollars, and they take years to be concluded. He requested to know if the GTL’s “scorched earth” lawsuit would have a positive impact on the firm and the virtuousness of its financial activities. Securus will keep offering responses to the misleading claims of its competitor and also affirm its patents. Mr. Smith believes that the methods that GTL is using in handling issues are ineffective since Securus Technologies is a more established enterprise that has a wide patent portfolio.


Richard also offered a statement about the latest information that GTL provided to the press. He said that he would like to welcome its competitor to a technology challenge at any time. According to him, his company has been offering opportunities to GTL to proof the potential of its products. The firm has not taken on the encounter, and it has been offering many press reports. GTL has not offered any statement on Securus’ corrections.


Mikhail Blagosklonny Commitment to Finding Cancer Treatment

Mikhail Blagosklonny is a proficient professor at the Rosewell Park Cancer Institute. The institution was established with an aim of helping cancer patients through their healing process. Mikhail is also a degree holder in internal medicine and a PhD holder in experimental medicine from the First Pavlov State Medical University of St Peterburg on LinkedIn. He has used his passion for cancer and aging to develop hypothesis regarding the relation between cancer and aging on patients.

Prior to working at Rosewell Park Cancer Institute, Mikhail worked as an associate professor of medicine at New York Medical College and as a senior scientist at Ordway Research Institute. He is passionate about anti-aging drugs and treatments, cancer therapies and treatments on He is currently working to prove his hypothesis that proposes the use of rapamycin drug for the treatment of cancer with the aim of increasing the patients’ life expectancy.

His research and interests include ontogenesis, cell cycle, mitosis and other cancer related issues that are affecting individuals. Mikhail Blagosklonny also conducts clinical investigations and examinations on the same with the intention of coming up with possible solutions of the same. Despite being a scientist, he is also an editor. He is the chief editor for Cell Cycle, Aging and Oncotarget. Moreover, he is one of the board members of Cancer Biology and Therapy. He has more than 270 peer reviewed journals published in his name and has been cited by reliable and credible science authors and researchers.

He believes that cancer has a cure and that through his research and other people’s commitment to studying the disease, there is hope for humanity. His empathy for the communities and the people suffering from the deadly disease is his driving force. It gives him the motivation to conduct hundreds of clinical experiments to get the solution to aging and cancer. Also, through the publications and the research articles that he writes, he believes he can answer the many questions that patients ask themselves. Source: